Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevantolol - SOM Biotech

Next Previous
Drug Profile

Bevantolol - SOM Biotech

Alternative Names: Bevantolol-hydrochloride; CI-775; NC-1400; SOM-3355

Latest Information Update: 19 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Chemiphar
  • Developer SOM Biotech
  • Class Antidementias; Antihypertensives; Ischaemic heart disorder therapies; Neuroprotectants; Phenethylamines; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Preclinical Tardive dyskinesia

Most Recent Events

  • 19 Aug 2025 Preclinical trials in Tardive dyskinesia in Spain (unspecified route), prior to August 2025 (SOM Biotech pipeline, August 2025)
  • 15 Jul 2024 SOM Biotech completes a phase II trial in Huntington's disease (In adults, In the elderly) in France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom (PO), after August 2022 (NCT05475483)
  • 28 Mar 2022 SOM Biotech initiates a phase II trial in Huntington's disease (In adults, In the elderly) in Spain (PO) (EudraCT2021-003453-28) (NCT05475483)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top